We have previously demonstrated that there is a low level of transcription of tissue-specific genes in every cell type. In this study, we (lymphoid cells). In Becker cases with out-of-frame deletions, the already described alternatively spliced species found in muscle samples were also found in nonspecific cells. These results demonstrate that illegitimate transcripts are a bona fide version of tissuespecific mRNA, and that they represent a useful material to investigate the qualitative consequences of gene defects at the mRNA level. (J. Clin. Invest. 1991Invest. . 88:1161Invest. -1166
Introduction
Molecular characterization of unknown mutations in disease genes based on DNA analysis is laborious, especially when the gene is very large, with numerous exons and undefined exon/ intron junctions (e.g., the genes responsible for Duchenne (DMD)' and Becker (BMD) muscular dystrophies, cystic fibrosis, neurofibromatosis type 1). In theory, searching for unknown mutations is much easier ifmRNA is used as a source of genetic material, since the coding sequence is more compact in mRNA than in DNA. We have already demonstrated that the defects found in transcripts from a ubiquitously expressed gene, such as a subunit of f,-hexosaminidase A, faithfully reflect the DNA abnormality (1, la). However, this strategy is 1. Abbreviations used in this paper: BMD, Becker muscular dystrophy; c, complementary; DMD, Duchenne muscular dystrophy; i, identical; LCL, lymphoblastoid cell lines; PCR, polymerase chain reaction.
restricted by difficulties in obtaining mRNA from tissue-specific genes (e.g., muscle, brain, liver, pancreas, heart).
We have developed a cDNA-polymerase chain reaction (PCR) method to detect and quantitate minute amounts of dystrophin mRNA (2) . With this method, we could detect and characterize dystrophin transcripts in specific cells (striated, smooth muscle, and brain), and also in nonspecific cells, such as cultured lymphoblastoid cells. The unexpected finding of a ubiquitous basal level of transcription of a tissue-specific gene was also observed with other genes, such as the genes for fl-globin, anti-hemophilic factor VIIIC, and antimullerian hormone (3) . This phenomenon was coined "illegitimate" transcription by our group (3) , and "ectopic" transcription by Sarkar et al. (4) . We have previously demonstrated that normal illegitimate transcripts found in lymphoblasts, lymphocytes, and fibroblasts are a bona fide version of normal tissue-specific mRNAs. However, the processing of illegitimate transcripts produced by abnormal genes had not yet been investigated.
In this study we report the results of analysis performed on cDNA-PCR-amplified dystrophin mRNA in fibroblasts, blood cells, or lymphoblasts from eight Duchenne and three Becker patients with internal deletion of the dystrophin gene. Qualitative analysis consisted in sequencing the truncated transcripts resulting from internal deletions of the dystrophin gene, using appropriate combinations of primers amplifying across the predicted junction points.
We found that the sequence oftruncated transcripts around the junction point of the deletion corresponds precisely to the one deduced from the genomic deletion and is identical in legitimate (muscle) and in illegitimate (non-muscle cells) transcripts. In BMD cases with deletion transgressing the reading frame rule (5) (see Discussion), analysis performed on illegitimate transcripts reveals, as in muscle RNA (6) , the presence of alternatively spliced transcripts restoring the reading frame. This indicates that the illegitimate transcription allows us to study easily the consequences of a gene mutation on the processing in tissues other than their normal sites of expression.
Methods
Clinical classification ofpatients and deletion analysis. The patients were classified as Duchenne (wheelchair-bound by age 12), or Becker (wheelchair-bound at age 16 or later). In all cases, the diagnosis was ascertained by serum creatine kinase activity and muscle histological pattern. Deletion breakpoints in the dystrophin gene were mapped relative to exons by Southern blot analysis of HindIII digests of genomic DNA, using cDNA probes covering 9 kb of dystrophin cDNA (7) . In some cases, additional studies included EcoRI and BglII maps and PCR amplification of specific exons.
Source ofRNA and RNA analysis. Total RNA was extracted from the following sources: (a) EBV-immortalized lymphoblastoid cell lines; (b) peripheral blood lymphocytes; (c) cultured fibroblasts. Total cellular RNAs were purified by the method of Chirgwin et al. (8) and were checked by agarose gel electrophoresis followed by ethidium bromide staining.
Oligonucleotide primers were synthetized according to the dystrophin sequence published by Koenig et al. (9) . Nucleotide sequence of primers complementary (c) and identical (i) to mRNA sequence are indicated in figures and legends.
cDNA-PCR coamplification of several fragments ofthe dystrophin transcript was performed as described in detail in Chelly et al. (10) . cDNA was synthetized (using 5-10 jug total RNA) by simultaneous extension of different dystrophin-specific primers (lOc, 44c, and 62c). In some cases, the cDNA was synthetized by random priming using hexanucleotide primers as a template to the reverse transcriptase enzyme (MMLV, BRL). After this first step, coamplification was carried out with three couples ofprimers corresponding to the dystrophin transcript (see Fig. 1 ). Reaction products (after 30 or 40 cycles) were subjected to polyacrylamide gel electrophoresis, transferred to a nylon membrane, and hybridized to labelled internal oligoprobes or cDNA probes (see figures).
Cloning and sequence analysis ofabnormal transcripts. Truncated transcripts ofthe dystrophin gene from DMD and BMD patients were amplified by PCR using primers flanking the junction points. For illegitimate transcripts present in nonspecific cells (lymphoid cells and fibroblasts), it was necessary to perform an additional run of 30 cycles of amplification using either the same primers or nested primers (see figures). The amplified fragments were separated by electrophoresis in a low melting agarose gel (4% NuSieve; FMC Corp., Rockland, ME) or in polyacrylamide gel (8%, wt/vol). Gels were stained with ethidium bromide, and the specific fragments, previously attested by specific hybridization and restriction map analysis, were cut out, purified, phosphorylated, and ligated into Smal digested M13 mplO vector. Sin- 
Results
Detection ofmature transcripts ofthe dystrophin gene in nonmuscle cultured cellsfrom DMD and BMD patients. We have screened by PCR coamplification three different portions of the dystrophin mRNA (see Fig. 1 a) from cultured lymphoblastoid cell lines (LCL), fibroblasts, and peripheral blood cells: (a) a 201-nt segment in the 5' region; (b) a 170-nt segment in the middle part of the transcript; (c) a 125-nt segment in the 3' region. In all samples from these 11 patients (8 DMD and 3 BMD) with previously detected internal gene deletions, the three dystrophin mRNA segments were detected, only if the primers were outside of the deleted region of the transcript (Table I and Fig. 1 b) . Owing to the very low level ofdystrophin illegitimate transcripts in these cells, 30 PCR cycles had to be performed, and the amplified specific fragments were only detectable by hybridization with a radioactive probe, or visualized after a second run using nested primers. No dystrophin mRNA quantitation could be performed in these nonspecific cells (see Discussion). Sequence analysis ofthejunction point oftruncated dystrophin mRNA in lymphoblasts from DMD patients. To investigate the structure ofthe truncated dystrophin mRNAs, we used primers flanking the deleted exons to amplify the transcript of lymphoblastoid cells from DMD patients. In Fig. 2 , we show typical results obtained in a DMD case with an internal out-offrame deletion encompassing exons 44-47 (patient 5, Table I and Fig. 2 ). Using primers in exons 43 and 48, we amplified a sequence of 90 bp, which hybridized to the 44.1 cDNA probe (1 1) and was cut by Ddel, as expected (Fig. 2 . In this figure we showed the dystrophin transcript analysis in lymphoblasts from patients [1] [2] [3] [4] [5] (Table I) . Analysis ofdystrophin transcripts in cases in which thephenotype (BMD) is in contradiction with the reading frame hypothesis. We have applied the strategy of PCR amplification of truncated transcripts to study the dystrophin transcripts in three unrelated BMD with an out-of-frame deletion (patients 9, 10, and 11, table I).
Patient 9, 21 yrs old, had a dystrophin gene deletion removing exons 3-7 which disrupts the reading frame (12) . The dystrophin transcripts were investigated in lymphoblastoid cells fragment was subcloned, and three independent clones were sequenced. Each of them gave the expected sequence and showed that exons 43 and 48 were precisely abutted (Fig. 2 b) . As shown in Fig. 2 c, there is a stop codon 49 nucleotides downstream of the junction point.
We checked that the truncated dystrophin transcript found in lymphoblastoid cells from DMD patients was identical to that found in skeletal muscle. Fig. 3 shows results obtained in a DMD case (patient 8) , in which exons 7-13 were deleted. and in muscle. To explore the expected truncated transcript, as well as other species resulting from conceivable alternative splicing, cDNA-PCR amplification was performed using two couples of primers, located in exons 1 and 8, and exons 1 and 10, respectively. In lymphoblastoid cells, results obtained after 30 cycles and confirmed by specific hybridization are the following: in addition to the expected truncated transcript in which exons 2 and 8 are juxtaposed, we found three additional species illustrated by a 144-bp and an 8 1-bp segment (Fig. 4 a) with the Eli-ElOc primer couple and by a 93-bp segment (data not shown) with the primers located in exons 1 (El i) and 8 (E8c). The sequencing and exon-specific hybridization data showed that the three additional transcript species correspond to different splicing patterns: between exons 2 and 10 (Fig. 4, a  and c) , between exons 1 and 10 (Fig. 4 a) , and between exons 1 and 8 (data not shown). In each case, the exons were precisely spliced, without any sequence abnormality, other than the random errors due to the Taq polymerase. Among the different splicing patterns observed, only the juxtaposition of exon 1 to exon 8 and ofexon 2 to exon 10 restore the reading frame. The species corresponding to alternative splicing were not detected in control lymphoblastoid cells (data not shown).
Patient 10 (12) is another patient with a typical Becker phenotype and a deletion removing exons 3-7 of the dystrophin gene which disrupts the reading frame. The dystrophin transcripts were explored in peripheral blood lymphocytes, using the same primers as in the preceding case. Similar results were obtained, but in this case the species corresponding to the inframe 2-10 splicing was more abundant than in patient 9.
Quantitative and qualitative analysis ofthe dystrophin gene products (transcript and protein levels) performed on muscle biopsy ofthese two BMD patients and on normal control muscle have been described in detail elsewhere (6).
Patient 11 had a Becker clinical pattern and a dystrophin gene deletion removing exon 50 only (13) , which should result in an out-of-frame transcript. In this case, the only available source ofdystrophin mRNA was cultured fibroblasts, in which the truncated dystrophin transcript was amplified by PCR (40 cycles) using primers located in exons 49 and 52. A segment of 350 bp, hybridizing to cDNA probe 44.1 (Fig. 5 a) , was detected. This fragment was cut by Rsal and Ddel as expected (data not shown). After a second run of PCR using nested primers, two species of transcripts were obtained: a major one, represented by the fragment of -300 bp, and a minor one,
represented by the fragment of 70 bp long. The nucleotide sequence of the major species detected in the patient's fibroblasts confirmed that it corresponds precisely to an out-offrame 49-51 transcript, with a stop codon 30 nucleotides downstream of the junction point (Fig. 5 c) . The minor and smaller species hybridizes to 44.1 cDNA probe and possibly corresponds to a 49-52 alternatively spliced species which would restore the reading frame (Fig. 5 a) . In normal muscle, the fragment which corresponded to this 49-52 alternative splicing was already detected after the first round of PCR (segment of -120 bp, Fig. 5 a) . E52c. 2 E52c Figure 5 . Analysis of truncated dystrophin transcripts in fibroblasts from a Becker patient with out-of-frame deletion of exon 50. (P 22 is designated as patient 11 in Table I scripts from specific tissues (1 3a) . This faithful illegitimate transcription offers the invaluable advantage ofgiving access to abnormal transcripts using easily available cells. In this study we generally used EBV-established LCL, and, occasionally, peripheral blood lymphocytes and cultured fibroblasts. We sequenced the illegitimate dystrophin transcripts across thejunction points in nonspecific cells from five cases with internal deletions ofthe dystrophin gene. In all ofthem, we detected the expected transcript corresponding precisely to the one deduced from DNA analysis using cDNA probes. We checked that the sequence of the illegitimate truncated dystrophin transcripts found in lymphoid cells from three patients (two BMD and one DMD, this study and results already described in 6) was identical to that of the legitimate truncated transcripts present in muscle. Possible contamination inherent in the PCR procedure was eliminated on the following basis: (a) an RNA sample prepared from lymphoblasts of a patient with a 4-megabase deletion encompassing the whole dystrophin gene (patient JM, described in 14) was regularly used as a negative control; (b) in two cases (patients 5 and 1 1), for which we had no sample other than lymphoblastoid cells or fibroblasts, the truncated illegitimate transcript, never found in normal material, could not originate from a contaminant.
The difficulty encountered in this type of analysis is the scarcity of the illegitimate transcripts, which correspond to far less than one copy per cell (3). However, we have observed that their abundance could be increased by translation inhibitors such as cycloheximide (1 3a). To get enough material for qualitative studies including sequence analysis, it is usually necessary to perform a second run of PCR amplification using nested primers. It should be emphasized that, in standard culture conditions, the abundance ofthe illegitimate transcripts is variable (1 3a), which precludes any use of illegitimate transcription to quantitate the abundance of abnormal mRNAs.
Monaco et al. (5) postulated that internal deletions disrupting the reading frame of the dystrophin gene result in the Duchenne phenotype, whereas those which maintain the reading frame result in the Becker phenotype. This has been verified in 92% ofthe cases (7, 15) . In this study, among three BMD cases representing apparent exceptions to the reading frame rule, two exceptions concerning exons 3-7 out-of-frame deletions were analyzed (patients 9 and 10). This deletion is the most frequent one in the 5' region of the gene giving rise to Becker disease (16) . In both cases, the out-of-frame transcript with the expected truncation, i.e., containing exons 1, 2, and 8, was found; however, three minor additional transcripts, resulting from alternative splicing, were also found. Two ofthem, joining exons 2 and 10 and exons 1 and 8, respectively, restore the reading frame, while the third one, less abundant, joins exons 1 and 10 and is still out-of-frame. We have also looked for alternative splicing in one patient with an out-of-frame deletion ofexon 50 and clinically classified as BMD (case 1 1). In fibroblasts, the only material available from this patient, we found the expected out-of-frame 49-51 transcript as a major species, and minute amounts of an alternatively spliced in-frame 49-52 transcript.
These results, which are qualitatively identical to those obtained on muscle from the BMD patients with an out-of-frame deletion that removes exons 3-7 (6) , demonstrate that the impact of gene abnormalities on mRNA processing is similar in specific and in presumably nonexpressing cell types and could suggest that the milder BMD phenotype may be due to translation of the minor alternatively spliced in-frame transcripts.
The major expected application is the direct analysis of point mutation in nonspecific accessible cells of tissue-specific transcripts produced by mutant genes. Berg et al. (17) and Knebelman et al. (18) have taken advantage of this illegitimate or ectopic transcription to detect a novel point mutation in the FVIIIC gene causing hemophilia A and a nonsense mutation in the antimullerian hormone gene associated with the persistent mifllerian duct syndrome, respectively. Schldsser et al. (19) and Roberts et al. (20) have used this phenomenon to characterize pathological dystrophin transcripts from the lymphocytes of a muscular dystrophy carrier.
Our data on abnormal transcripts investigated in nonmuscle tissue specimens from DMD and BMD patients extend the practical usefulness of the analysis of illegitimate transcripts corresponding to tissue-specific genes and suggest that illegitimate transcription could also be exploited (a) to characterize mRNA splicing defects that may occur at high frequency in complex genes, and (b) to understand correlations between gene abnormalities and clinical phenotype.
